News

New Section: Publications

We have compiled an overview of imusyn-featured publications.

Felzartamab is partially DTT-resistant

In our new publication ⧉, we examined whether different anti-CD38 antibodies behave in the same way when it comes to mitigating their interference in pre-transfusion testing by DTT.

Interference of therapeutic biologics

In our new review ⧉ we look at how therapeutic biologics targeting CD20, CD38 and CD47 can interfere with serological and pre-transfusion testing.

T Cell Staining Reagent available now

Visit our shop to discover Dyemer, imusyn's novel T cell staining reagent.

Or have a look at our unmatched panel of recombinant HLA class I and class II proteins.

imuPep Class I Peptide Binding Analysis

Our innovative, high-throughput service for you to confirm your target peptides, e.g. in vaccine and cancer research.

New IFU Versions

New versions and languages of the IFU for DaraEx plus are now available (release 2026/06/10).

New versions of the IFU for rBGA are available (release 2025/05).

Certificate Available for Download

EN ISO 13485:2016 + AC:2018 + A11:2021, issued March 30^th, 2026, and Certificate Directive 98/79/EC, issued May 20^th, 2022, can be found here.

Publications

This section provides access to scientific publications featuring imusyn, alongside a selection of imusyn's conference posters available for direct download.

Articles, Case Studies, and Reviews

2026

Zeretzke A, Trummer P, Habicht CP, Schneeweiss C. Not all anti-CD38 antibodies are created equal: The epitope of felzartamab is partially DTT-resistant. Transfusion Medicine. 2026; 1-6. doi:10.1111/tme.70112 ⧉
Trummer P, Habicht CP, Scharberg EA, Schneeweiß C. Therapeutic biologics interference in serological and pre-transfusion testing. Frontiers in Immunology. 2026; 17:1888597. doi:10.3389/fimmu.2026.1888597 ⧉

2025

Habicht CP, Adolph S, Grüger D, Hervatin R, Immenschuh S, Králová J, et al. Anti-CD47 drug interference in pre-transfusion testing can be overcome by antigen masking. Transfusion. 2025; 65(10): 1914–1921. doi:10.1111/trf.18367 ⧉
Habicht CP, Schneeweiss C. Antigen masking indirect antiglobulin test can mitigate the interference of Mezagitamab, a novel anti-CD38 antibody, in serological pre-transfusion testing. Transfusion Medicine. 2025; 35(4): 385-389. doi:10.1111/tme.13139 ⧉

2024

Habicht C, Hervatin R, Grüger D, Immenschuh S, Adolph S, Schneeweiß C. Immunhämatologische Interferenz im Verlauf einer Anti-CD47-Antikörpertherapie. Transfusionsmedizin. 2024; 204–208. doi:10.1055/a-2139-2189 ⧉ (German)

2023

Weinig E, Rink G, Stürtzel A, Seyboth S, Grüger D, Schneeweiß C, et al. KNMB, a novel Knops blood group antigen located in LHR-C. Transfusion. 2023; 63(11): E56–E58. doi:10.1111/trf.17541 ⧉
Habicht CP, Ridders M, Grueger D, Adolph S, Immenschuh S, Schneeweiss C. Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform? Transfusion. 2023; 63(4): 808–816. doi:10.1111/trf.17253 ⧉

2021

Grüger D, Immenschuh S, Hervatin R, Schneeweiß C. Immunhämatologische Daratumumab-Interferenz im Verlauf einer Myelomtherapie. Transfusionsmedizin. 2021; 11(04): 241–244. doi:10.1055/a-1521-8045 ⧉ (German)

2020

Grueger D, Zeretzke A, Habicht CP, Skaik Y, Wagner FF, Scharberg EA, et al. Two novel antithetical KN blood group antigens may contribute to more than a quarter of all KN antisera in Europe. Transfusion. 2020; 60: 2408–2418. doi:10.1111/trf.16039 ⧉

2019 - 2010

Stieglitz F, Celik AA, von Kaisenberg C, Camps MA, Blasczyk R, Bade-Döding C. The microstructure in the placenta is influenced by the functional diversity of HLA-G allelic variants. Immunogenetics. 2019 Jul;71(7):455-463. doi:10.1007/s00251-019-01121-0 ⧉
Schneeweiß C, Grüger D, Heuft HG. DaraEx verhindert Daratumumab-Interferenz im indirekten Antihumanglobulintest. Transfusionsmedizin. 2017; 7: 229–232. doi:10.1055/s-0043-113808 ⧉ (German)
Seltsam A, Wagner F, Lambert M, Bullock T, Thornton N, Scharberg EA, et al. Recombinant blood group proteins facilitate the detection of alloantibodies to high-prevalence antigens and reveal underlying antibodies: results of an international study. Transfusion. 2014; 54: 1823–1830. doi:10.1111/trf.12553 ⧉

Conference Posters, Presentations, and Abstracts

2026

Spindler J, Grüger D, Hallensleben M, Immenschuh S, Schneeweiß C. Bennett-Goodspeed Revisited: Analysis of Human Leukocyte Antigens on Red Blood Cells Confirms an Undeclared Blood Group System. DGTI 2026. P040.
Grüger D, Habicht CP, Lauwers M, Akiki P, Hogerheijde L, Ligthart P, Schneeweiß C. Soluble recombinant CD36 Neutralizes Anti-CD36 Antibodies. DGTI 2026. P042.
Grüger D, Habicht CP, Spindler J, Schneeweiß C. CD36-Enhanced Red Blood Cells Improve the Detectability of anti-CD36 Antibodies in the Indirect Antiglobulin Test. DGTI 2026. P057.
Habicht CP, Posset M, Brosig A, Züger M, Kahle K, Loeser E, Budde M, Immenschuh S, Schneeweiß C. From Anti-CD38 Interference to Diagnosis: Real-World Multicenter Experience with DaraEx plus. DGTI 2026. P063.
Habicht CP, Grüger D, Schneeweiß C. A new coat for red blood cells: detection of donor specific anti-HLA antibodies in the indirect antiglobulin test. DGTI 2026. FV059 ⧉
Schneeweiß C, Zeretzke A, Knutzen P, Verboom M, Blasczyk R. Recombinant SLA Class I and II Molecules for Xenotransplantation Diagnostics. EFI 2026. P197.

2019 - 2010

Schneeweiß C, Grüger D, Blasczyk R. Daratumumab Interference in Red Cell Antibody Detection: Specific Inhibition with DaraEx. DGTI 2017. P06-5 ⧉
Filchtinski D, Blasczyk R, Schneeweiß C. NKG2D Binding Strength Depends on Allelic MICB Variation: Possible Implications for NK Cell Mediated Killing. EFI 2015. P169 ⧉